Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-guided tamoxifen therapy: time to pause for reflection?

The Lancet. Oncology - 1 Aug 2009

Lash Timothy L, Lien Ernst A, Sørensen Henrik Toft, Hamilton-Dutoit Stephen

Abstract excerpt

Tamoxifen remains a cornerstone of adjuvant therapy for patients with early stage breast cancer and oestrogen-receptor-positive tumours. Accurate markers of tamoxifen resistance would allow prediction of tamoxifen response and personalisation of combined therapies. Recently, it has been suggested that patients with inherited non-functional alleles of the cytochrome P450 CYP2D6 might be poor candidates for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Biomarkers, Tumor
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Drug Resistance, Neoplasm

Share to Neoplasm Recurrence, Local

Share to Receptors, Estrogen

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 19647203
DOI: 10.1016/S1470-2045(09)70030-0
PMCID: PMC2895727

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-guided tamoxifen therapy: time to pause for reflection?PMID 19647203Read ↗

Genotype-guided adjuvant endocrine therapy: new tricks from an old drug?Semantic proximity Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Semantic proximity Read ↗

CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons LearnedSemantic proximity Read ↗

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.Semantic proximity Read ↗

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.Semantic proximity Read ↗

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?Semantic proximity Read ↗

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.Semantic proximity Read ↗

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.